UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
For quarterly period ended December 31, 1994 or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission file number 1-9860
BARR LABORATORIES, INC.
(Exact name of Registrant as specified in its charter)
New York 22-1927534
(State or Other Jurisdiction of (I.R.S. -Employer
Incorporation or Organization) Identification No.)
Two Quaker Road, P. O. Box 2900, Pomona, New York 10970-0519
(Address of principal executive offices)
914-362-1100
(Registrant's telephone number)
(Former name, former address and former fiscal year, if changed
since last report)
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes X NO
Number of shares of Common Stock, Par Value $.01, outstanding as
of December 31, 1994: 8,751,178.
Amending Part I. Item 1. Financial Statements
Consolidated Statements of Cashflow
<PAGE>
<TABLE>
BARR LABORATORIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
For The Six Months Ended December 31, 1994 and 1993
(thousands of dollars, unaudited)
<CAPTION>
1994 1993
CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES:
<S> <C> <C>
Net earnings $4,093 $532
Adjustments to reconcile net earnings
to net cash from (used in) operating
activities:
Depreciation and amortization 2,045 1,689
Deferred income tax benefit (438) -
Cumulative effect of accounting change - (374)
Gain on disposal of equipment (87) (5)
Changes in assets and liabilities:
(Increase) decrease in:
Accounts receivable (6,870) (8,204)
Inventories (1,817) (8,012)
Prepaid expenses (203) (326)
Other assets (42) (198)
Increase (decrease) in:
Accounts payable, accrued liabilities
and income taxes payable 8,167 12,630
Net cash from (used in) operating activities 4,848 (2,268)
CASH FLOWS FROM (USED IN) INVESTING ACTIVITIES:
Purchases of property, plant and equipment (3,166) (1,846)
Proceeds from sale of property, plant and
equipment 300 36
Net cash used in investing activities (2,866) (1,810)
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES:
Principal payments on long-term debt (35) (82)
Proceeds from exercise of stock options
and employee stock purchases 336 472
Net cash from financing activities 301 390
Increase (decrease) in cash 2,283 (3,688)
Cash and cash equivalents at beginning of
period 36,499 25,048
Cash and cash equivalents at end of period $38,782 $21,360
Supplemental cash flow data-Cash paid during
the period:
Interest, net of portion capitalized $1,398 $1,298
Income taxes $1,791 -
<FN>
See accompanying notes to the consolidated financial statements.
</TABLE>
<PAGE>
BARR LABORATORIES, INC. AND SUBSIDIARIES
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
BARR LABORATORIES, INC.
Dated: March 28, 1995 /s/ Bruce L. Downey
Bruce Downey, Chairman,
Chief Executive Officer and President
Dated: March 28, 1995 /s/ Paul M.Bisaro
Paul M. Bisaro, Chief Financial Officer
and General Counsel
Dated: March 28, 1995 /s/ Peter J. Finnerty
Peter J. Finnerty, Corporate Controller
